WallStSmart

Ardent Health Partners, Inc. (ARDT)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 939% more annual revenue ($66.57B vs $6.41B). MRK leads profitability with a 4.8% profit margin vs 1.2%. ARDT trades at a lower P/E of 19.6x. ARDT earns a higher WallStSmart Score of 40/100 (F).

ARDT

Hold

40

out of 100

Grade: F

Growth: 3.3Profit: 4.5Value: 5.3Quality: 6.5
Piotroski: 4/9Altman Z: 2.05

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARDT.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.94

$62.10 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARDT1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

ARDT4 concerns · Avg: 3.0/10
Market CapQuality
$1.57B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.7%3/10

ROE of 7.7% — below average capital efficiency

Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ARDT

The strongest argument for ARDT centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : ARDT

The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 1.68 is elevated, increasing financial risk. Thin 1.2% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ARDT carries more volatility with a beta of 0.70 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARDT scores higher overall (40/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ardent Health Partners, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Ardent Health Partners, Inc. is a leading healthcare organization based in Nashville, Tennessee, focused on providing high-quality, patient-driven care through an extensive network of hospitals and outpatient facilities. The company emphasizes innovation and operational excellence, offering a comprehensive range of acute care services tailored to the specific needs of the communities it serves. With a solid financial foundation and a strategic growth plan, Ardent is well-prepared to enhance healthcare access and improve patient outcomes in a dynamic healthcare environment.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?